Table 3.

Therapeutic approaches and outcomes in patients treated with palliative intent (N = 8).

Treatment or outcome, No of patients (%)	Data value
First-line therapy	8 (8/13, 62)
Platinum and etoposide	4/8 (50)
Other platinum-based doublet	2/8 (25)
Chemotherapy and immune checkpoint inhibitor	2/8 (25)
Second-line therapy	1 (8)
Exposure rate
Platinum agent	8/8 (100)
Etoposide	4/8 (50)
Taxane	2/8 (25)
Immune checkpoint inhibitor	3/8 (37.5)
Best overall response
First-line therapy
CR or PR	4/8 (50)
SD	1/8 (12.5)
PD	3/8 (37.5)
Second-line therapy
PD	1 (100)

CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease